Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04705454 |
Expanded Access Status :
No longer available
First Posted : January 12, 2021
Last Update Posted : May 12, 2021
|
Sponsor:
ADC Therapeutics S.A.
Information provided by (Responsible Party):
ADC Therapeutics S.A.
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Brief Summary:
The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.
Condition or disease | Intervention/treatment |
---|---|
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Biological: Loncastuximab Tesirine |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |
Resource links provided by the National Library of Medicine

MedlinePlus related topics:
Lymphoma
Drug Information available for:
Loncastuximab tesirine
Intervention Details:
- Biological: Loncastuximab Tesirine
Other Name: Zynlonta
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Criteria
Inclusion Criteria:
- Male or female patient aged 18 years or older
- Pathologic diagnosis of DLBCL
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials
- Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least six months after the last dose of loncastuximab tesirine. Men with female partners who are of childbearing potential must agree that they will use a highly effective method of contraception from the time of giving informed consent until at least six months after the patient receives his last dose of loncastuximab tesirine
Exclusion Criteria:
- Known history of hypersensitivity to or positive serum human Anti-Drug Antibodies to loncastuximab tesirine
- Total bilirubin >1.5 x upper limit of normal (ULN)
- Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that ADCT Head of Medical Affairs and/or designee, and treating physician agree and document should not be exclusionary
- Autologous Stem Cell Transplantation (SCT) within 30 days prior to start of loncastuximab tesirine
- Allogeneic SCT within 60 days prior to start of loncastuximab tesirine
- Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
- Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease
- Breastfeeding or pregnant
- Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to starting loncastuximab tesirine, except shorter if approved by ADCT
- Use of any other experimental medication within 14 days prior to starting loncastuximab tesirine
- Any other significant medical illness, abnormality, or condition that would, in the treating physician's judgment, make the patient inappropriate to receive loncastuximab tesirine or put the patient at risk
No Contacts or Locations Provided
Responsible Party: | ADC Therapeutics S.A. |
ClinicalTrials.gov Identifier: | NCT04705454 |
Other Study ID Numbers: |
ADCT-402 EAP |
First Posted: | January 12, 2021 Key Record Dates |
Last Update Posted: | May 12, 2021 |
Last Verified: | May 2021 |
Keywords provided by ADC Therapeutics S.A.:
Expanded Access Lymphoma Large B-Cell Relapsed Refractory |
Additional relevant MeSH terms:
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases |
Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Loncastuximab tesirine Antineoplastic Agents, Immunological Antineoplastic Agents |